Rarity Public Benefit Corporation is trying to turn a UCLA cure for a rare disease into a medicine. The bottleneck now is not showing that it works, but another key part of the drug approval process — developing the commercial manufacturing. Great story by @carolynyjohnson.bsky.social 🧪